Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $1.8 million.

  • Eton Pharmaceuticals' Change in Accured Expenses rose 21114.98% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 22245.4%. This contributed to the annual value of $1.5 million for FY2024, which is 4008.88% down from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Change in Accured Expenses stood at $1.8 million, which was up 21114.98% from $172000.0 recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Change in Accured Expenses ranged from a high of $2.0 million in Q4 2024 and a low of -$1.6 million during Q1 2024
  • Its 5-year average for Change in Accured Expenses is $321631.6, with a median of $368000.0 in 2021.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 423000.0% in 2023, then plummeted by 23228.41% in 2024.
  • Over the past 5 years, Eton Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $120000.0 in 2021, then crashed by 153.33% to -$64000.0 in 2022, then surged by 2246.88% to $1.4 million in 2023, then skyrocketed by 48.69% to $2.0 million in 2024, then decreased by 12.58% to $1.8 million in 2025.
  • Its Change in Accured Expenses stands at $1.8 million for Q3 2025, versus $172000.0 for Q2 2025 and -$1.4 million for Q1 2025.